Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Press Releases

Trovagene Appoints Charlie Rodi, Ph.D., as Chief Technology Officer
PR Newswire

SAN DIEGO, Feb. 14, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of transrenal molecular diagnostics, today announced that Charlie Rodi, Ph.D. has been named Vice President and Chief Technology Officer. Dr. Rodi brings a wealth of management and scientific leadership to the position. While at G.D. Searle he was among the first to use nucleic acid biomarkers in the development of pharmaceuticals. He was also the Director of the Monsanto Genome Sequencing Center and served on both the Genomics Leadership Team and the Genomics Business Team. At Sequenom, Inc. he held the position of Executive Vice President, Genomics and was responsible for the development of a suite of technologies for the discovery, scoring, and determination of allelic frequency of disease-associated SNPs (single nucleotide polymorphisms). More recently, he established, at ICx BioSystems, the use of digital PCR in the detection of rare alleles in circulating nucleic acids and transcript profiling in circulating tumor cells. In addition to his expertise and innovation in the detection of nucleic acids, Dr. Rodi has been awarded several NIH grants in the area of infectious diseases. 

Upon joining the company Dr. Rodi stated, "I am delighted to be part of this experienced team. The most certain benefit of the Human Genome Project has always been molecular diagnostics. The competitive advantages that transrenal nucleic acids provide over other methods has uniquely positioned Trovagene, Inc. to be a leader in the field of nucleic acids based diagnostics. This is a great opportunity to impact the standard of care in cancer and other diseases."

Antonius Schuh, Ph.D., Trovagene's Chief Executive Officer noted that "Dr. Rodi has been working with the Trovagene leadership team as a consultant since December, 2011, and has contributed greatly to the company's strategy of mutation detection in the management of cancer and in optimizing its program in human papilloma virus detection. We are very pleased to have him involved in the commercialization of Trovagene's technology and assays."

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Trovagene has filed a Form 10 with the SEC. More complete current information about Trovagene is contained in the filing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.


Trovagene, Inc.
Stephen Zaniboni
Chief Financial Officer
+1 (858) 496-7466

Venanzio Ciampa
+1 (212) 217 9065


SOURCE Trovagene, Inc.

Web Site: http://www.trovagene.com